Anzeige
Mehr »
Login
Sonntag, 21.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Breaking News: Voller Fokus auf NurExone Biologic!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PNH3 | ISIN: US14843C1053 | Ticker-Symbol:
NASDAQ
19.04.24
21:59 Uhr
19,250 US-Dollar
+0,050
+0,26 %
1-Jahres-Chart
CASTLE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
CASTLE BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur CASTLE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.04.Castle Biosciences fortifies support of Esophageal Cancer Awareness Month with fundraising, educational collabs2
05.04.What Makes Castle Bioscience (CSTL) a Prospective Investment?2
04.04.Castle Biosciences Inc.: Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer273If choosing to use a molecular test to rule-out a sentinel lymph node biopsy (SLNB) in patients diagnosed with melanoma, it is important to show that patients foregoing an SLNB have low risk outcomes...
► Artikel lesen
27.03.CASTLE BIOSCIENCES INC - 8-K, Current Report1
22.03.Castle Biosciences CEO sells over $128k in company stock1
05.03.Earnings call: Castle Biosciences Exceeds Expectations in 20231
29.02.Castle Biosciences Inc reports results for the quarter ended in December - Earnings Summary3
28.02.Castle Biosciences files for $300M mixed securities shelf4
28.02.CASTLE BIOSCIENCES INC - S-8, Securities to be offered to employees in employee benefit plans1
28.02.Castle Biosciences GAAP EPS of -$0.10 beats by $0.46, revenue of $66.12M beats by $4.95M2
28.02.Recap: Castle Biosciences Q4 Earnings1
28.02.CASTLE BIOSCIENCES INC - 10-K, Annual Report1
28.02.CASTLE BIOSCIENCES INC - 8-K, Current Report1
28.02.Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results164FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results...
► Artikel lesen
27.02.Earnings Preview For Castle Biosciences1
26.02.Castle Biosciences study backs melanoma test over AJCC staging1
08.01.CASTLE BIOSCIENCES INC - 8-K, Current Report1
08.01.Castle Biosciences raises FY23 revenue, to exceed $210M above consensus2
08.01.Castle Biosciences Expects FY23 Revenue To Exceed $210 Mln, Surpassing Previous Outlook2
08.01.Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results222FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary...
► Artikel lesen
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1